Cover: The Cost and Health Effects of Prescription Drug Coverage and Utilization in the Medicare Population

The Cost and Health Effects of Prescription Drug Coverage and Utilization in the Medicare Population

Published Nov 18, 2005

by Baoping Shang

Download eBook for Free

FormatFile SizeNotes
PDF file 0.4 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 provides prescription drug coverage for virtually all seniors. The cost estimates for the Medicare prescription drug coverage are based on the expected per beneficiary utilization but do not take into account the potential offset by savings on other medical services. To estimate these savings, the author examines the effects of Medigap prescription drug benefit on elderly prescription drug spending, Medicare Part A spending, and Medicare Part B spending. It compares spending and service use for beneficiaries who have Medigap insurance, which may or may not cover prescription drugs, and uses variation in state regulations of the individual insurance market-including guaranteed issues and community rating-as instruments for prescription drug coverage. The author estimates that Medigap prescription drug coverage significantly increases drug spending by 22% and reduces Medicare Part A spending by 10–13%. Medicare Part B spending is reduced by an insignificant amount. The results imply that a $1 increase in prescription drug spending is associated with $1.63–$2.05 reduction in Medicare spending. The dissertation also considers the lifetime effects of anti-hypertensives on health outcomes and healthcare expenditures. The results suggest that controlling hypertension in the elderly could be very cost-effective.

Research conducted by

This document was submitted as a dissertation in October, 2005 in partial fulfillment of the requirements of the doctoral degree in public policy analysis at the Pardee RAND Graduate School. The faculty committee that supervised and approved the dissertation consisted of Dana Goldman (Chair), Geoffrey Joyce, and Darius Lakdawalla.

This publication is part of the RAND dissertation series. Pardee RAND dissertations are produced by graduate fellows of the Pardee RAND Graduate School, the world's leading producer of Ph.D.'s in policy analysis. The dissertations are supervised, reviewed, and approved by a Pardee RAND faculty committee overseeing each dissertation.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.